The India RUO immunoassay market is expected to grow at a CAGR of 12.91% from 2025 to 2030.
India’s RUO immunoassay market is mainly driven by government support towards nurturing the innovation ecosystem. The ICMR has set up centers of excellence at seven IITs for product development, along with five ICMR Centers for Advanced Research (CAR) focused on testing, preclinical and clinical evaluation, and validation. This initiative aims to bolster the Make in India MedTech sector.
India ranks as the fourth largest medical device market in Asia, following Japan, China, and South Korea, and is also among the top 20 medical device markets worldwide. Medical device exports from India amounted to Rs. 19,803 crore (US$ 2.40 billion) in the fiscal year 2021-2022. From April to December 2022, medical device exports reached Rs. 20,511 crore (US$ 2.49 billion). Projections by IBEF indicate that these exports are expected to grow substantially, reaching US$ 10 billion by the year 2025.
The market is expanding, and exports are rising due to various initiatives. These include the implementation of a system for export labeling, clarification on clinical evaluation and adverse event reporting, extension of the validity of free sales certificates by state licensing authorities from 2 years to 5 years for facilitating exports, and the creation of a list of manufacturers with export licenses to facilitate easier access by regulatory authorities worldwide.
India faces a significant burden of chronic diseases like diabetes, cancer, and others. RUO immunoassays are crucial research tools for development. India’s diabetes estimates (20-79 y) were 74,194.7 in 2021 and are expected to rise to 92,973.7 by 2030 (number in 1,000s). The number of cancer cases estimated by the government was 1,496,972 in 2023 and would rise to 1,533,055 in 2024. These figures further elaborate on the necessity for research and diagnostics tools for monitoring these conditions.
Further favorable developments are also contributing to the market growth. For example, Fujirebio Holdings, Inc. and Agappe Diagnostics Ltd announced a Contract Development and Manufacturing Organization (CDMO) partnership for the Cartridge CLIA system reagents manufacturing project for the immunology equipment Mispa i60 and Mispa i121.
The analyzers and reagents will be marketed under the Agappe brand, establishing Agappe as the first Indian company to offer a comprehensive Chemiluminescence Solution featuring locally manufactured reagents. This will provide high-quality, affordable, and unique Chemiluminescence solutions for the country.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| India RUO Immunoassay Market Size in 2025 | US$1.666 billion |
| India RUO Immunoassay Market Size in 2030 | US$2.345 billion |
| Growth Rate | CAGR of 12.91% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | Maharashtra, Tamil Nadu, Karnataka, Uttar Pradesh, Others |
| List of Major Companies in the India RUO Immunoassay Market | |
| Customization Scope | Free report customization with purchase |
India RUO Immunoassay Market Segmentation
By Product Type
By Sample Type
By Application
By End-User
By State